Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Loracarbef Anhydrous. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.66 |
| ▸ | HSD17B10 | Q99714 | 7/20 | 0.66 |
| ▸ | MAPT | P10636 | 6/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.66 |
| ▸ | TDP1 | Q9NUW8 | 6/20 | 0.66 |
| ▸ | MEN1 | O00255 | 5/20 | 0.66 |
| ▸ | HPGD | P15428 | 4/20 | 0.66 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.66 |
| ▸ | SLC15A2 | Q16348 | 4/20 | 0.66 |
| ▸ | LMNA | P02545 | 3/20 | 0.66 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.66 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.66 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.66 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.66 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.66 |
| ▸ | BLM | P54132 | 2/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Loracarbef Anhydrous SCHEMBL1819705 | 1.00 | KDM4E (0.66) | KDM4EALDH1A1HSD17B10MAPTKMT2A | |
| Loracarbef Anhydrous SCHEMBL34153 | 1.00 | KDM4E (0.66) | KDM4EALDH1A1HSD17B10MAPTKMT2A | |
| Loracarbef Anhydrous SCHEMBL9017047 | 1.00 | KDM4E (0.66) | KDM4EALDH1A1HSD17B10MAPTKMT2A | |
| Loracarbef Anhydrous SCHEMBL12306378 | 1.00 | KDM4E (0.66) | KDM4EALDH1A1HSD17B10MAPTKMT2A | |
| Loracarbef Anhydrous SCHEMBL2453036 | 1.00 | KDM4E (0.66) | KDM4EALDH1A1HSD17B10MAPTKMT2A | |
| Loracarbef Anhydrous SCHEMBL10692457 | 1.00 | KDM4E (0.66) | KDM4EALDH1A1HSD17B10MAPTKMT2A | |
| Loracarbef Anhydrous SCHEMBL13457172 | 1.00 | KDM4E (0.66) | KDM4EALDH1A1HSD17B10MAPTKMT2A | |
| Loracarbef Anhydrous SCHEMBL17530968 | 1.00 | KDM4E (0.66) | KDM4EALDH1A1HSD17B10MAPTKMT2A | |
| Loracarbef Anhydrous SCHEMBL17530291 | 1.00 | KDM4E (0.66) | KDM4EALDH1A1HSD17B10MAPTKMT2A | |
| Loracarbef Anhydrous SCHEMBL1229813 | 0.99 | KDM4E (0.67) | KDM4EALDH1A1HSD17B10MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1295 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260027140-A1 | COMPOSITIONS AND METHODS FOR TREATING AND AMELIORATING RESPIRATORY CONDITIONS AND INFLAMMATION OF MUCOSA | ATOPIC MEDICAL INC (US) | 2026-01-29 | — | — | US | claimed |
| US-12371429-B2 | Antibiotic resistance-modifying tricyclic heteroaryl compounds and uses thereof | RECREO PHARMACEUTICALS LLC (US) | 2025-07-29 | — | — | US | claimed |
| US-20230414584-A1 | ADMINISTRATION OF ANTIBIOTIC COMPOUNDS FOR THE TREATMENT OF STREPTOCOCCAL INFECTIONS FOR THE TREATMENT OF PSORIASIS | CENTRE FOR DIGESTIVE DISEASES (AU) | 2023-12-28 | — | — | US | claimed |
| CN-116650492-A | Administration of antibiotic compounds for the treatment of streptococcal infections to treat psoriasis | 消化系统疾病中心 | 2023-08-29 | — | — | CN | claimed |
| EP-3836919-A1 | 1,3,4,9-TETRAHYDRO-2H-PYRIDO[3,4-B]INDOLE DERIVATIVE COMPOUNDS AND USES THEREOF | Recreo Pharmaceuticals Inc. (US) | 2021-06-23 | — | — | EP | claimed |
| US-20210163479-A1 | 1,3,4,9-TETRAHYDRO-2H-PYRIDO[3,4-B]INDOLE DERIVATIVE COMPOUNDS AND USES THEREOF | RECREO PHARMACEUTICALS LLC (US) | 2021-06-03 | — | — | US | claimed |
| CN-112654354-A | 1,3,4, 9-tetrahydro-2H-pyrido [3,4-b ] indole derivative compound and application thereof | 菲尼克思药业股份有限公司 | 2021-04-13 | — | — | CN | claimed |
| EP-3684373-A1 | COMPOSITIONS AND METHODS FOR TREATING AND AMELIORATING RESPIRATORY CONDITIONS AND INFLAMMATION OF MUCOSA | Atopic Medical, LLC (US) | 2020-07-29 | — | — | EP | claimed |
| WO-2020037155-A1 | 1,3,4,9-TETRAHYDRO-2H-PYRIDO[3,4-B]INDOLE DERIVATIVE COMPOUNDS AND USES THEREOF | RECREO PHARMACEUTICALS LLC (US) | 2020-02-20 | — | — | WO | claimed |
| CN-110234322-A | Administration of antibiotic compounds for the treatment of streptococcal infections to treat psoriasis | 消化系统疾病中心 | 2019-09-13 | — | — | CN | claimed |
| US-7396527-B2 | degrade in the body to release a beta-lactam antibiotic and a beta-lactamase inhibitor; drug delivery | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2008-07-08 | — | — | US | claimed |
| CN-1994301-A | Heterocyclic compounds which are active as inhibitors of beta lactamases | AVENTIS PHARMA SA (FR) | 2007-07-11 | — | — | CN | claimed |
| CN-1791437-A | Medical implants comprising biocompatible coatings | BLUE MEMBRANES GMBH (DE) | 2006-06-21 | — | — | CN | claimed |
| CN-1681497-A | Dispersible tablets for oral administration | RANBAXY LAB LTD (IN) | 2005-10-12 | — | — | CN | claimed |
| US-20050100526-A1 | Antibiotic polymers | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2005-05-12 | — | — | US | claimed |
| WO-2003066053-A1 | ANTIBIOTIC POLYMERS | RUTGERS, THE STATE UNIVERSITY (US) | 2003-08-14 | — | — | WO | claimed |
| US-20020042394-A1 | Cobalamin compounds useful as antibiotic agents and as imaging agents | HOGENKAMP HENRICUS P C (US) | 2002-04-11 | — | — | US | claimed |
| CN-1337881-A | Use of organophosphorous compounds for preventing or treating infections | JOMAA PHARMACEUTIC AG (DE) | 2002-02-27 | — | — | CN | claimed |
| WO-2001092288-A2 | COBALAMIN COMPOUNDS USEFUL AS ANTIBIOTIC AGENTS AND AS IMAGING AGENTS | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2001-12-06 | — | — | WO | claimed |
| CN-1319006-A | Use of organophosphorous compounds for producing medicaments for therapeutic and prophylactic treatment of infections or as fungicide, bactericide or herbicide for plants | JOMAA PHARMACEUTICALS AG (DE) | 2001-10-24 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12371429-B2 | Antibiotic resistance-modifying tricyclic heteroaryl compounds and uses thereof | CBR3, CBR1, CYP2B6 | KDM4E 3576/4885ALDH1A1 1459/4885HSD17B10 928/4885 |
| US-20260027140-A1 | COMPOSITIONS AND METHODS FOR TREATING AND AMELIORATING RESPIRATORY CONDITIONS AND INFLAMMATION OF MUCOSA | IL1B, IL5, SERPINB1 | KDM4E 4014/4885ALDH1A1 4294/4885HSD17B10 3520/4885 |
| US-20050100526-A1 | Antibiotic polymers | MGAM, PARG, PARN | KDM4E 2106/4885ALDH1A1 2426/4885HSD17B10 793/4885 |
| US-20210163479-A1 | 1,3,4,9-TETRAHYDRO-2H-PYRIDO[3,4-B]INDOLE DERIVATIVE COMPOUNDS AND USES THEREOF | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CCNA1, FOXM1 | KDM4E 3824/4885ALDH1A1 767/4885HSD17B10 2407/4885 |
| US-20020042394-A1 | Cobalamin compounds useful as antibiotic agents and as imaging agents | MMAB, BLVRB, AHCY | KDM4E 4257/4885ALDH1A1 3866/4885HSD17B10 3277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.